Navigation Links
Scripps Florida awarded $7.6 million grant to develop novel treatment for Parkinson's disease
Date:3/12/2008

Philip LoGrasso, associate professor and senior director for drug discovery at Scripps Florida, will lead the project as principal investigator. LoGrasso, who joined Scripps Florida in 2005, previously held positions at Merck and the NIH.

The new five-year grant will fund research to develop a compound to treat neurodegeneration in Parkinsons disease. The goal of the project is to bring the potential treatment to the point where Scripps Research and potential partners can file an application for an investigational new drugthe first step in the lengthy clinical trials process required by the U.S. Food and Drug Administration.

An estimated one million Americans are believed to suffer from Parkinson's disease, according to the Parkinsons Disease Foundation; approximately 40,000 new cases are reported annually. Patients with Parkinsons suffer from a loss of dopaminergic neurons, the source of dopamine, a neurotransmitter that plays a key role in motor reflexes and cognitition. While some loss of dopaminergic neurons is common, Parkinsons patients routinely lose more than half.

Development of a drug that prevents dopaminergic neurodegeneration would be a quantum leap in the clinical treatment of Parkinsons disease, LoGrasso said. All current therapies treat only the symptoms of the disease, not the underlying pathologies. Current treatments also tend to lose therapeutic efficacy over time, or have adverse side effect profiles that make their long-term use difficult.

A Classic Approach

To develop the new small-molecule compound, LoGrasso will work with a team of Scripps Research scientists. Together, the team represents a range of experience in pharmaceutical preclinical drug development, encompassing the fields of medicinal chemistry, biochemistry, cell biology, structural biology, behavioral pharmacology, drug metabolism and pharmacokinetics, and toxicology.

The team will use what LoGrasso calls a classical pharmaceutical approach to drug development, which involves annual milestones and multiple compound tracking.

Our research plan is designed to mitigate the risk of developing a single compound that may fail due to specific problems, and to maximize the chance for clinical success by having back-up compounds, LoGrasso said. We believe that using this approach to optimize small-molecule inhibitors will create a series of compounds with favorable pharmacokinetic properties and safety profiles.

The scientists will examine small-molecule compounds that inhibit c-jun-N-terminal kinase 2/3 (JNK 2/3). Pronounced Junk, JNK 2/3 is an important contributor to stress-induced apoptosis (cell death) and has been shown to play a significant role in neuronal survival. As such, the kinase is a highly viable target for drugs to treat neurodegenerative disorders like Parkinsons disease.

Previous research has shown that small-molecule and peptide inhibitors of the JNK target protect dopaminergic neurons in both acute and chronic models of Parkinsons disease. Previous research has also shown that the JNK2/3 knockout mouse modelsmice that lack the gene for JNK2/3suffer fewer Parkinsons-like symptoms.

The scientists hope to identify approximately three compounds that demonstrate in vivo efficacy by the third year, and a top compound by year four of the research program.

When were finished, our aim it is to have a safe, efficacious compound with sufficient preclinical safety data to support human clinical studies, LoGrasso said.


'/>"/>

Contact: Keith McKeown
kmkeown@scripps.edu
858-784-8134
Scripps Research Institute
Source:Eurekalert

Related medicine news :

1. Scripps Research scientists shed new light on how antibodies fight HIV
2. Scripps Health Treats More Than 160 Fire Victims at Emergency Departments Across San Diego County
3. Scripps research scientists discover chemical triggers for aggression in mice
4. Scripps research scientists find new genetic mutation that halts the development of lupus
5. Scripps scientists find calcium channel blockers help normalize lysosomal storage disease cells
6. Scripps scientists peg wind as the force behind fish booms and busts
7. Scripps research scientists devise approach that stops HIV at earliest stage of infection
8. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
9. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
10. Judge Rules That Florida Disease Management Program Serving 8,000 HIV/AIDS Patients Should Be Re-bid, Says AIDS Healthcare Foundation
11. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... , ... August 18, 2017 , ... ... financial planning assistance that serves communities throughout southern Florida, is working to support ... scholarship assets to children from low income families. , The Take Stock In ...
(Date:8/18/2017)... ... August 18, 2017 , ... With over 16,000 active patients, ... replacement therapy and integrative medicine, has become a frontrunner for people seeking help ... menopause, andropause, thyroid disorder and adrenal insufficiencies. , Founded in 2003 by ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Our Mountains to Climb: A ... a couple that grew stronger together through the faith they shared to overcome struggles ... is the creation of published author, Barbara J. Corcoran, a retired teacher and happily ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... marketers of high-quality anti-aging skincare solutions, recently announced the launch of ... products are an affordable, yet effective alternative to expensive plastic surgery or in-patient ...
(Date:8/17/2017)... ... August 17, 2017 , ... ... a new location in Goldsboro, NC to its family of practices. Residents of ... Associates’ trademark starting August 15, 2017. , Riccobene Associates Family Dentistry, founded ...
Breaking Medicine News(10 mins):
(Date:7/31/2017)... 31, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), has been ... Michigan by Crain,s Detroit Business . ... companies by three-year revenue growth. This year,s edition measures growth ... To view the complete list, visit crainsdetroit.com/awards/fast_50/2017 .  ... incredible triumph," said Phil Hagerman , CEO and chairman ...
(Date:7/28/2017)... CHICAGO, July 28, 2017 Hill-Rom Holdings, Inc. ... fiscal third quarter ended June 30, 2017, and updated ... For the fiscal third quarter, ... to $0.68 per diluted share in the prior-year period. ... of $0.39 per diluted share primarily related to the ...
(Date:7/27/2017)... Services, Inc. (NYSE: WST ) today announced ... financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record high, ... constant currency (organic) grew by 3.9%. ... in the prior-year quarter. Second-quarter 2017 adjusted diluted EPS ...
Breaking Medicine Technology: